MedTrace Logo

Pertussis Challenge Study in Adults Vaccinated With BPZE1

NCT05461131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-03-12

Study results available
· View outcomes & findings →

Summary

This is a randomised, double-blinded, placebo-controlled trial of BPZE1 that includes virulent B. pertussis challenge followed by a safety follow-up.

Conditions

  • Pertussis/Whooping Cough
  • Bordetella Pertussis, Whooping Cough

Interventions

BIOLOGICAL

BPZE1

Live attenuated vaccine

BIOLOGICAL

Placebo

Placebo

DRUG

Azithromycin

Antibiotic

OTHER

Bordetella Pertussis Challenge Strain

Challenge Strain

Sponsors & Collaborators

  • ILiAD Biotechnologies

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-20
Primary Completion
2023-07-25
Completion
2023-10-26
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461131 on ClinicalTrials.gov